Crinetics (CRNX) announced that the first patient has been dosed in the BALANCE-CAH Phase 2/3 trial evaluating investigational candidate atumelnant, a novel, once-daily oral adrenocorticotropic hormone receptor antagonist candidate for the proposed treatment of classic congenital adrenal hyperplasia in children and adolescents.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- ‘Markets Climb Wall-of-Worry’: Oppenheimer Sees Resilience Driving 2026 and Suggests 2 Stocks to Buy
- Crinetics Highlights Breakout Year and Strong Endocrinology Pipeline
- Crinetics Pharmaceuticals: Phase 2 TouCAHn De‑Risking and Optimized Phase 3 Design Drive Upgrade to Buy and $67 Target
- Crinetics upgraded to Buy from Neutral at Goldman Sachs
- Crinetics price target raised to $87 from $80 at Morgan Stanley